OPR - Delayed Quote • USD CRBP Jun 2024 50.000 call (CRBP240621C00050000) Follow 6.10 0.00 (0.00%) As of April 5 at 3:00 PM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for CRBP240621C00050000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: CRBP Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher? 7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares Retail investors in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) are its biggest bettors, and their bets paid off as stock gained 214% last week Corbus Pharmaceuticals Announces Pricing of Public Offering Corbus Pharmaceuticals Announces Proposed Public Offering
